Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.92 |
| ▸ | NPC1 | O15118 | 2/20 | 0.77 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.77 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.77 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.77 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.77 |
| ▸ | AHR | P35869 | 1/20 | 0.61 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.61 |
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7439873 | 0.98 | MAPT (0.89) | MAPTNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL518954 | 0.96 | MAPT (1.00) | MAPTNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL21120273 | 0.90 | MAPT (0.89) | MAPTNPC1MAPK13MAPK12MAPK11 | |
| Oxalic Acid SCHEMBL8173155 | 0.87 | MAPT (0.83) | MAPTNPC1MAPK13MAPK12MAPK11 | |
| Sulfuric Acid SCHEMBL6194221 | 0.87 | MAPT (0.83) | MAPTNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL10032 | 0.87 | NPC1 (1.00) | MAPTNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL4227502 | 0.87 | NPC1 (1.00) | MAPTNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL29365738 | 0.87 | NPC1 (1.00) | MAPTNPC1MAPK13MAPK12MAPK11 | |
| Hydrochloric Acid SCHEMBL30293252 | 0.85 | NPC1 (0.96) | MAPTNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL23766313 | 0.84 | MAPT (0.67) | MAPTNPC1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021190-B1 | Amid derivatives as growth hormone release promotors | KAKEN PHARMA CO LTD (JP) | 2006-11-08 | — | — | EP | claimed |
| US-6914069-B2 | Pharmaceutically active compounds and methods of use | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-07-05 | — | — | US | claimed |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| US-4692522-A | Benzofused lactams useful as cholecystokinin antagonists | MERCK & CO., INC. (US) | 1987-09-08 | — | — | US | disclosed |
| US-4684645-A | GASTROINTESTINAL AND NERVOUS SYSTEM DISORDERS | MERCK & CO., INC. (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0166354-A2 | Benzofused lactam compounds and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-01-02 | — | — | EP | disclosed |
| US-4537885-A | SUBSTITUTED 1-CARBOXY-3-(CARBOXYMETHYLAMINO)-2-ONE DERIVATIVES, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | CIBA GEIGY CORPORATION (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0119161-A2 | Benzazocinone and benzazoninone derivatives, process for their preparation, pharmaceutical preparations containing these compounds, and their therapeutical use | CIBA-GEIGY AG (CH) | 1984-09-19 | — | — | EP | disclosed |
| US-4470988-A | HYPOTENSIVE AGENTS, ENZYME INHIBITOR, CARDIAC DISORDERS | CIBA-GEIGY CORPORATION (US) | 1984-09-11 | — | — | US | disclosed |
| EP-0107095-A1 | 1-N-alkylcarboxy-benzofused lactams useful as antihypertensive agents | MERCK & CO. INC. (US) | 1984-05-02 | — | — | EP | disclosed |
| US-4107303-A | Antihypertensive hexafluorohydroxyisopropyl benzazepines and benzazocines | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-08-15 | — | — | US | disclosed |
| US-4008267-A | ANALYZING | AB KABI (SW) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MAPT 4206/4885NPC1 991/4885MAPK13 203/4885 |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MAPT 4206/4885NPC1 991/4885MAPK13 203/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | MAPT 4206/4885NPC1 991/4885MAPK13 203/4885 |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | MAPT 4206/4885NPC1 991/4885MAPK13 203/4885 |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MAPT 4206/4885NPC1 991/4885MAPK13 203/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MAPT 4206/4885NPC1 991/4885MAPK13 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.